Skip to main content
SpringerLink
Log in

Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

In order to reduce the pain due bone metastases a last generation bisphosphonate, 2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid, was labeled with 188Re and investigated further. Labeling was performed at 95 °C for 15 min. The stability of radioconjugate was checked in human serum at 37 °C and biodistribution was studied in balb/c mice. Labeling yield of ≥98 % was obtained corresponding to a specific activity of 46 MBq/µmol. The radioconjugate showed good stability in human serum. Our main achievement was high bone uptake (4.24 ± 0.12 % ID/g at 24 h post injection) which may therapeutically be beneficial for the palliation of painful bone metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:73–84

    Article  CAS  Google Scholar 

  2. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1–18

    Article  CAS  Google Scholar 

  3. Uppelschoten JM, Wanders SL, de Jong JM (1995) Single-dose radiotherapy (6 Gy): palliation in painful bone metastases. Radiother Oncol 36:198–202

    Article  CAS  Google Scholar 

  4. Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T (2003) Bone metastases are a severe problem in oncology, since they usually are associated with pain. Oncol Rep 10:399–404

    Google Scholar 

  5. McEwan AJ (2000) Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 10:103–114

    Article  CAS  Google Scholar 

  6. Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365

    CAS  Google Scholar 

  7. Elder RC, Yuan J, Helmer B, Pipes D, Deutsch K, Deutsch E (1997) Studies of the structure and composition of rhenium-1,1-hydroxyethylidenediphosphonate (HEDP) analogues of the radiotherapeutic agent (186)ReHEDP. Inorg Chem 36:3055–3063

    Article  CAS  Google Scholar 

  8. Lam MG, de Klerk JM, van Rijk PP (2004) 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 31(Suppl 1):S162–S170

    Article  CAS  Google Scholar 

  9. Castronovo EP, Callahan RJ (1972) New bone scanning agent: 99mTc-labeled 1-hydroxy-ethylidene-1, 1-disodium phosphonate. J Nucl Med 13:823–827

    CAS  Google Scholar 

  10. Cocquyt V, Kline WF, Gertz BJ, van Belle SJ, Holland SD, DeSmet M, Quan H, Vyas KP, Zhang KE, De Greve J, Porras AG (1999) Pharmacokinetics of intravenous alendronate. J Clin Pharmacol 39:385–393

    Article  CAS  Google Scholar 

  11. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS (1999) Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 55:234–243

    Article  CAS  Google Scholar 

  12. Smith MR (2008) Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol: Semin Orig Investig 26:420–425

    Article  CAS  Google Scholar 

  13. Neves M, Gano L, Pereira N, Costa MC, Costa MR, Chandia M, Rosado M, Fausto R (2002) Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl Med Biol 29:329–338

    Article  CAS  Google Scholar 

  14. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91

    Article  CAS  Google Scholar 

  15. Maxon HR III, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI (1990) Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 176:155–159

    Article  Google Scholar 

  16. Robinson RJ (1990) Systemic radioisotopic therapy of primary and metastatic bone cancer. J Nucl Med 31:1326–1327

    CAS  Google Scholar 

  17. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF Jr, Biersack HJ (2000) Dose escalation study with rhenium-186 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med 27:123–130

    Article  CAS  Google Scholar 

  18. Arano Y, Ono M, Wakisaka K, Uezono T, Akizawa H, Motonari Y (1995) Synthesis and biodistribution studies of 186Re complex of 1-hydroxyethylidene-1,1-diphosphonate for treatment of painful osseous metasitases. Radioisotopes 44:514–522

    Article  CAS  Google Scholar 

  19. De Winter F, Brans B, Van De Wiele C, Dierckx RA (1999) Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clin Nucl Med 24:898–899

    Article  Google Scholar 

  20. Limouris GS, Skukla SK (1997) Gastric uptake in Re-186 HEDP bone scintigraphy. Anticancer Res 17:1779–1782

    CAS  Google Scholar 

  21. Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR (1986) The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl Med Biol 4:465–477

    Google Scholar 

  22. Verdera ES, Gaudiano J, Leon A, MartõÂnez G, Robles A, Savio E (1997) Rhenium-188-HEDP kit formulation and quality control. Radiochim Acta 79:113–117

    CAS  Google Scholar 

  23. Bai HS, Jin XH, Wang F, Du J, Liu YM, Chen DM (1996) Preparation of a cold kit of186Re(Sn)-HEDP. J Radioanal Nucl Chem 206:43–50

    Article  CAS  Google Scholar 

  24. Janoki GA, Polyak A, Kiraly R, Balogh L, Korosi L, Mathe D (2007) Comparative evaluation of therapeutic radiopharmaceuticals. International atomic energy agency, Vienna, p 103

    Google Scholar 

  25. Lin WY, Hsieh JF, Lin CP, Hsieh BT, Ting G, Wang SJ, Knapp FFR (1999) Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes. Nucl Med Biol 26:455–459

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 14395-836, Tehran, Iran

    Mostafa Erfani & Seyed Pezhman Shirmardi

  2. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, P.O. Box: 61357-33184, Ahvaz, Iran

    Alireza Doroudi & Mohammad Amin Dinari

Authors
  1. Mostafa Erfani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alireza Doroudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Amin Dinari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Pezhman Shirmardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mostafa Erfani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erfani, M., Doroudi, A., Dinari, M.A. et al. Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy. J Radioanal Nucl Chem 303, 2027–2032 (2015). https://doi.org/10.1007/s10967-014-3813-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-014-3813-7

Keywords

Search

Navigation